Do analysts rate PRTC or RXRX?

Recursion Pharmaceuticals has a consensus target price of $8.06, indicating a potential upside of 130.29%. Given Recursion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Recursion Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has higher earnings and valuation, PRTC or RXRX?

PureTech Health has higher earnings, but lower revenue than Recursion Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Recursion Pharmaceuticals $74.68M 25.09 -$644.76M -$1.04 N/A

Does the media refer more to PRTC or RXRX?

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Recursion Pharmaceuticals and 1 mentions for PureTech Health. Recursion Pharmaceuticals' average media sentiment score of 0.69 beat PureTech Health's score of 0.00 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Recursion Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PRTC or NTLA?

Intellia Therapeutics has a consensus price target of $21.15, indicating a potential upside of 64.74%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Intellia Therapeutics 4 Sell rating(s) 8 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.35

Which has preferable earnings & valuation, PRTC or NTLA?

PureTech Health has higher earnings, but lower revenue than Intellia Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Intellia Therapeutics $59.51M 30.24 -$412.69M -$3.36 N/A

Does the media favor PRTC or NTLA?

In the previous week, Intellia Therapeutics had 4 more articles in the media than PureTech Health. MarketBeat recorded 5 mentions for Intellia Therapeutics and 1 mentions for PureTech Health. Intellia Therapeutics' average media sentiment score of 1.21 beat PureTech Health's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PRTC or BCAX?

Bicara Therapeutics has a consensus price target of $32.64, indicating a potential upside of 36.55%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.80

Which has stronger earnings & valuation, PRTC or BCAX?

PureTech Health has higher revenue and earnings than Bicara Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Bicara Therapeutics N/A N/A -$137.95M -$3.10 N/A

Is PRTC or BCAX more profitable?

PureTech Health's return on equity of 0.00% beat Bicara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PureTech Health N/A N/A N/A Bicara Therapeutics N/A -41.49% -38.59%

Does the media favor PRTC or BCAX?

In the previous week, Bicara Therapeutics had 7 more articles in the media than PureTech Health. MarketBeat recorded 8 mentions for Bicara Therapeutics and 1 mentions for PureTech Health. Bicara Therapeutics' average media sentiment score of 0.64 beat PureTech Health's score of 0.00 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PRTC or ABSI?

Absci has a consensus target price of $13.43, suggesting a potential upside of 40.61%. Given Absci's stronger consensus rating and higher probable upside, analysts plainly believe Absci is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Absci 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78

Which has stronger valuation & earnings, PRTC or ABSI?

PureTech Health has higher revenue and earnings than Absci. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Absci $2.80M 585.31 -$115.18M -$0.80 N/A

Does the media prefer PRTC or ABSI?

In the previous week, Absci had 3 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Absci and 1 mentions for PureTech Health. Absci's average media sentiment score of 0.23 beat PureTech Health's score of 0.00 indicating that Absci is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Absci 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, TRAX or PRTC?

First Tracks Biotherapeutics has higher earnings, but lower revenue than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Is TRAX or PRTC more profitable?

Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A PureTech Health N/A N/A N/A

Does the media favor TRAX or PRTC?

In the previous week, First Tracks Biotherapeutics had 4 more articles in the media than PureTech Health. MarketBeat recorded 5 mentions for First Tracks Biotherapeutics and 1 mentions for PureTech Health. First Tracks Biotherapeutics' average media sentiment score of 0.30 beat PureTech Health's score of 0.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment First Tracks Biotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

PureTech Health (PRTC) Competitors

$17.42 0.00 (0.00%)

As of 08/21/2026

Compare

PRTC vs. RXRX, NTLA, BCAX, ABSI, and TRAX

Should you buy PureTech Health stock or one of its competitors? PureTech Health's main competitors and comparable companies include Recursion Pharmaceuticals (RXRX), Intellia Therapeutics (NTLA), Bicara Therapeutics (BCAX), Absci (ABSI), and First Tracks Biotherapeutics (TRAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PureTech Health compare to Recursion Pharmaceuticals?

PureTech Health (NASDAQ:PRTC) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Recursion Pharmaceuticals has a consensus target price of $8.06, indicating a potential upside of 130.29%. Given Recursion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

PureTech Health has higher earnings, but lower revenue than Recursion Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Recursion Pharmaceuticals	$74.68M	25.09	-$644.76M	-$1.04	N/A

PureTech Health has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. PureTech Health's return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

PureTech Health has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Recursion Pharmaceuticals and 1 mentions for PureTech Health. Recursion Pharmaceuticals' average media sentiment score of 0.69 beat PureTech Health's score of 0.00 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Recursion Pharmaceuticals beats PureTech Health on 8 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Intellia Therapeutics?

PureTech Health (NASDAQ:PRTC) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

PureTech Health has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market.

PureTech Health has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. PureTech Health's return on equity of 0.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

Intellia Therapeutics has a consensus price target of $21.15, indicating a potential upside of 64.74%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

PureTech Health has higher earnings, but lower revenue than Intellia Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Intellia Therapeutics	$59.51M	30.24	-$412.69M	-$3.36	N/A

0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Intellia Therapeutics had 4 more articles in the media than PureTech Health. MarketBeat recorded 5 mentions for Intellia Therapeutics and 1 mentions for PureTech Health. Intellia Therapeutics' average media sentiment score of 1.21 beat PureTech Health's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Intellia Therapeutics beats PureTech Health on 9 of the 15 factors compared between the two stocks.

How does PureTech Health compare to Bicara Therapeutics?

PureTech Health (NASDAQ:PRTC) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Bicara Therapeutics has a consensus price target of $32.64, indicating a potential upside of 36.55%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

0.0% of PureTech Health shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by company insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PureTech Health's return on equity of 0.00% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Bicara Therapeutics	N/A	-41.49%	-38.59%

PureTech Health has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, suggesting that its stock price is 175% less volatile than the broader market.

In the previous week, Bicara Therapeutics had 7 more articles in the media than PureTech Health. MarketBeat recorded 8 mentions for Bicara Therapeutics and 1 mentions for PureTech Health. Bicara Therapeutics' average media sentiment score of 0.64 beat PureTech Health's score of 0.00 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bicara Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

PureTech Health has higher revenue and earnings than Bicara Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

Summary

Bicara Therapeutics beats PureTech Health on 7 of the 13 factors compared between the two stocks.

How does PureTech Health compare to Absci?

PureTech Health (NASDAQ:PRTC) and Absci (NASDAQ:ABSI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

In the previous week, Absci had 3 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Absci and 1 mentions for PureTech Health. Absci's average media sentiment score of 0.23 beat PureTech Health's score of 0.00 indicating that Absci is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Absci	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

PureTech Health has higher revenue and earnings than Absci.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Absci	$2.80M	585.31	-$115.18M	-$0.80	N/A

Absci has a consensus target price of $13.43, suggesting a potential upside of 40.61%. Given Absci's stronger consensus rating and higher probable upside, analysts plainly believe Absci is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

0.0% of PureTech Health shares are held by institutional investors. Comparatively, 52.1% of Absci shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Comparatively, 10.5% of Absci shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

PureTech Health has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. PureTech Health's return on equity of 0.00% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Absci	-7,756.38%	-61.71%	-54.52%

PureTech Health has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Absci has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

Summary

Absci beats PureTech Health on 9 of the 14 factors compared between the two stocks.

How does PureTech Health compare to First Tracks Biotherapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, First Tracks Biotherapeutics had 4 more articles in the media than PureTech Health. MarketBeat recorded 5 mentions for First Tracks Biotherapeutics and 1 mentions for PureTech Health. First Tracks Biotherapeutics' average media sentiment score of 0.30 beat PureTech Health's score of 0.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
First Tracks Biotherapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

First Tracks Biotherapeutics currently has a consensus target price of $63.00, indicating a potential upside of 46.14%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe First Tracks Biotherapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

First Tracks Biotherapeutics has higher earnings, but lower revenue than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

0.0% of PureTech Health shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
PureTech Health	N/A	N/A	N/A

Summary

First Tracks Biotherapeutics beats PureTech Health on 5 of the 8 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTC vs. The Competition

Export

Metric	PureTech Health	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$424.04M	$4.01B	$7.37B	$12.83B
Dividend Yield	N/A	3.64%	2.53%	10.78%
P/E Ratio	N/A	11.62	272.33	24.21
Price / Sales	91.01	1,305.37	613.72	90.25
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	1.38	17.38	11.25	6.42
Net Income	-$109.74M	-$22.72M	$3.47B	$348.89M
7 Day Performance	N/A	3.29%	2.09%	0.08%
1 Month Performance	N/A	8.23%	6.64%	3.88%
1 Year Performance	-6.89%	55.05%	25.02%	16.98%

PureTech Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTC PureTech Health	0.0102 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100	News Coverage Upcoming Earnings
RXRX Recursion Pharmaceuticals	1.7265 of 5 stars	$3.09 -0.6%	$8.06 +160.8%	-29.1%	$1.69B	$74.68M	N/A	400
NTLA Intellia Therapeutics	3.234 of 5 stars	$11.60 -4.1%	$21.15 +82.3%	+22.1%	$1.67B	$67.67M	N/A	600	News Coverage Positive News
BCAX Bicara Therapeutics	2.1874 of 5 stars	$24.92 -0.1%	$32.64 +31.0%	+101.9%	$1.61B	N/A	N/A	32	Analyst Upgrade
ABSI Absci	2.2298 of 5 stars	$8.85 -4.2%	$13.43 +51.7%	+263.1%	$1.59B	$1.56M	N/A	210	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRTC) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PureTech Health (PRTC) Competitors

PRTC vs. RXRX, NTLA, BCAX, ABSI, and TRAX

How does PureTech Health compare to Recursion Pharmaceuticals?

Summary

How does PureTech Health compare to Intellia Therapeutics?

Summary

How does PureTech Health compare to Bicara Therapeutics?

Summary

How does PureTech Health compare to Absci?

Summary

How does PureTech Health compare to First Tracks Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PureTech Health (PRTC) Competitors

PRTC vs. RXRX, NTLA, BCAX, ABSI, and TRAX

How does PureTech Health compare to Recursion Pharmaceuticals?

Do analysts rate PRTC or RXRX?

Which has higher earnings and valuation, PRTC or RXRX?

Is PRTC or RXRX more profitable?

Which has more risk & volatility, PRTC or RXRX?

Does the media refer more to PRTC or RXRX?

Do institutionals & insiders believe in PRTC or RXRX?

Summary

How does PureTech Health compare to Intellia Therapeutics?

Which has more volatility and risk, PRTC or NTLA?

Is PRTC or NTLA more profitable?

Do analysts recommend PRTC or NTLA?

Which has preferable earnings & valuation, PRTC or NTLA?

Do insiders and institutionals believe in PRTC or NTLA?

Does the media favor PRTC or NTLA?

Summary

How does PureTech Health compare to Bicara Therapeutics?

Do analysts rate PRTC or BCAX?

Do insiders & institutionals believe in PRTC or BCAX?

Is PRTC or BCAX more profitable?

Which has more risk and volatility, PRTC or BCAX?

Does the media favor PRTC or BCAX?

Which has stronger earnings & valuation, PRTC or BCAX?

Summary

How does PureTech Health compare to Absci?

Does the media prefer PRTC or ABSI?

Which has stronger valuation & earnings, PRTC or ABSI?

Do analysts rate PRTC or ABSI?

Do insiders and institutionals hold more shares of PRTC or ABSI?

Is PRTC or ABSI more profitable?

Which has more volatility and risk, PRTC or ABSI?

Summary

How does PureTech Health compare to First Tracks Biotherapeutics?

Does the media favor TRAX or PRTC?

Do analysts prefer TRAX or PRTC?

Which has preferable valuation & earnings, TRAX or PRTC?

Do institutionals and insiders hold more shares of TRAX or PRTC?

Is TRAX or PRTC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools